Welcome to our dedicated page for FIREFLY NEUROSCIENCE SEC filings (Ticker: AIFF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Firefly Neuroscience, Inc. filings document the public-company disclosures of an AI precision-neuroscience business focused on EEG/ERP brain analytics and related software platforms. Its Form 8-K reports cover material financing agreements, including securities purchase agreements for unit issuances and at-the-market common stock sales arrangements, along with corporate events affecting its capital structure.
Proxy and annual meeting filings describe Firefly Neuroscience governance matters, including director elections, auditor ratification, incentive plan amendments, common stock voting mechanics and stockholder vote results. The filing record also provides formal disclosure context for the company’s operating model, commercialization activities, equity plan administration and governance obligations as a Nasdaq-listed Delaware corporation.
Firefly Neuroscience, Inc. reported continued operating losses for the quarter and six months ended June 30, 2026 while significantly expanding its balance sheet through equity financings. Revenue reached $514 thousand for the quarter and $999 thousand for the first half of 2026, up sharply from 2025 levels, largely driven by the Evoke Neuroscience acquisition and subscription-based deployments of its FDA-cleared Evoke EEG System across more than 85 U.S. sites.
Total assets rose to $16.8 million, with cash and cash equivalents increasing to $9.2 million from $2.7 million at year-end 2025, primarily due to March–April 2026 private placements that generated about $10.3 million in net proceeds. Shareholders’ equity improved to $14.7 million, although the company still carried an accumulated deficit of $115.6 million and an operating cash outflow of $3.7 million in the first half.
Management explicitly states that recurring losses, negative operating cash flows, and insufficient revenue raise substantial doubt about the ability to continue as a going concern within one year. An at-the-market facility of up to $7.4 million remains unused, and 14.6 million warrants plus equity awards represent significant potential dilution. Management also concludes that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 due to material weaknesses, with remediation efforts ongoing.
Firefly Neuroscience, Inc. held its 2026 annual meeting on August 5, 2026, where stockholders approved Amendment No. 2 to the 2024 Long-Term Incentive Plan, increasing the Plan Share Limit by 2,000,000 shares of common stock and updating the plan’s evergreen provision. Stockholders also elected Arun Menawat as a Class III director to serve until 2029 and approved, on a non-binding advisory basis, compensation for named executive officers.
Stockholders approved a charter amendment decreasing total authorized capital from 5,001,000,000 shares to 101,000,000, consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock, effective August 5, 2026. They ratified CBIZ Canada, LLP as independent auditor and approved an adjournment proposal. Shares outstanding on the June 8, 2026 record date were 15,604,571, with 9,703,536 shares represented, constituting a quorum.
Firefly Neuroscience, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on August 5, 2026 at 10 a.m. Eastern Time. Stockholders of record as of June 8, 2026, when 15,604,571 common shares were outstanding, are entitled to vote.
Proposals include electing Class III directors, ratifying CBIZ Canada, LLP as independent auditor for 2026, an advisory say-on-pay vote on named executive officer compensation, and approving Amendment No. 2 to the 2024 Long-Term Incentive Plan. Stockholders are also asked to approve a Certificate of Amendment to decrease the total number of authorized shares and to approve a potential adjournment of the meeting if more time is needed to solicit proxies.
The proxy details Board composition, independence, and committee structures, and discloses 2025 compensation, including $1,063,718 for CEO Greg Lipschitz and $748,335 for President and COO David DeCaprio. Directors and executive officers as a group beneficially own 6.90% of outstanding common stock.
Firefly Neuroscience, Inc. filed a resale registration covering up to 20,499,999 shares of its common stock for resale by identified selling stockholders.
The company states it is not selling any shares hereunder and will not receive proceeds from resales; it may receive proceeds only if the March 2026 Warrants are exercised for cash (full cash exercise would yield approximately $29,929,998). Shares outstanding were 15,605,821 as of July 1, 2026.
Firefly Neuroscience, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders. The meeting will be held on August 5, 2026 with the record date fixed as June 8, 2026. There were 15,064,571 shares outstanding as of the Record Date. The Board recommends voting for Proposals 1–6, which include election of Class III director(s), ratification of CBIZ Canada, LLP as auditors, an advisory vote on executive compensation, amendments to the 2024 Long-Term Incentive Plan, approval of an amendment to the certificate of incorporation to decrease authorized shares, and a proposal to adjourn if necessary. Proxy materials and the 2025 Form 10-K are available online.
Firefly Neuroscience, Inc. has terminated a previously agreed financing deal. The company and an accredited investor mutually ended a securities purchase agreement dated May 6, 2026, under which Firefly had planned to sell up to 666,667 units at $1.50 per unit, for potential gross proceeds of up to $1,000,000. The termination was agreed in writing and became effective on June 25, 2026, under Section 5.3 of the agreement. This update is reported as the termination of a material definitive agreement.
Firefly Neuroscience, Inc. registers up to 20,499,999 shares of common stock for resale. This preliminary prospectus covers resale by the identified Selling Stockholders of Registrable Securities issued in the March 2026 private placement, including shares issued and issuable upon exercise of related warrants.
The filing states the company will not receive proceeds from sales by the Selling Stockholders, although it may receive cash if the March 2026 Warrants are exercised for cash; full cash exercise at the stated exercise prices would generate approximately $29,929,998. Shares outstanding were 15,605,821 as of June 16, 2026, and outstanding after giving effect to the issuance described is shown as 36,105,820 in the prospectus.
Firefly Neuroscience, Inc. reports a change in the role and status of former Chief Technology Officer Gil Issachar. On June 18, 2026, Deel Innovation Ltd., which provides consulting services to Firefly, entered into an employment agreement with Issachar under which he now serves as Head of AI and Neuroscience for the company.
The new agreement supersedes all prior employment terms between Firefly and Issachar. Effective June 18, 2026, the board determined that Issachar is no longer classified as a Section 16 officer or executive officer of Firefly Neuroscience. The employment agreement is filed as Exhibit 10.1.
Firefly Neuroscience, Inc. registers up to 22,500,000 shares of common stock for resale by identified selling stockholders under a shelf prospectus. The registration covers shares issuable upon exercise of multiple warrant series from March and May 2026 private placements. Firefly will not receive proceeds from Selling Stockholder resales; the company may receive proceeds only if Warrants are exercised for cash. Shares outstanding were 15,571,780 as of May 15, 2026; outstanding after giving effect to the registered issuance is stated as 38,071,780.